Mpox vaccination and treatment: a systematic review

J Chemother. 2024 Apr;36(2):85-109. doi: 10.1080/1120009X.2023.2289270. Epub 2023 Dec 9.

Abstract

The Human monkeypox virus (mpox) belongs to the Poxviridae family, characterized by double-stranded DNA. A 2022 outbreak, notably prevalent among men who have sex with men, was confirmed by the World Health Organization. To understand shifting prevalence patterns and clinical manifestations, we conducted a systematic review of recent animal and human studies. We comprehensively searched PubMed, Scopus, Web of Science, Cochrane Library, and Clinicaltrials.gov, reviewing 69 relevant articles from 4,342 screened records. Our analysis highlights Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN)'s potential, though efficacy concerns exist. Tecovirimat emerged as a prominent antiviral in the recent outbreak. However, limited evidence underscores the imperative for further clinical trials in understanding and managing monkeypox.

Keywords: Monkeypox; mPV; mPXV; mpox; post-exposure; pre-exposure.

Publication types

  • Systematic Review

MeSH terms

  • Animals
  • Benzamides / therapeutic use
  • Disease Outbreaks
  • Humans
  • Mpox, Monkeypox* / drug therapy
  • Mpox, Monkeypox* / prevention & control
  • Sexual and Gender Minorities
  • Smallpox Vaccine*

Substances

  • Benzamides
  • Smallpox Vaccine
  • tecovirimat